Evaluation of the Effect of Carvedilol in Preventing Right Ventricular Dysfunction in Breast Cancer Patients Receiving Anthracycline.
Anthracycline
breast cancer
carvedilol
ejection fraction
right ventricle
Journal
Advanced biomedical research
ISSN: 2277-9175
Titre abrégé: Adv Biomed Res
Pays: India
ID NLM: 101586897
Informations de publication
Date de publication:
2023
2023
Historique:
received:
24
05
2021
revised:
11
01
2022
accepted:
19
01
2022
entrez:
17
3
2023
pubmed:
18
3
2023
medline:
18
3
2023
Statut:
epublish
Résumé
Today, it has been shown that it is possible for right ventricular (RV) wall motion abnormalities or RV functional disorders to occur during cancer treatment. Now, considering the effect of carvedilol on beta 1, 2, and alpha receptors and its antioxidant properties, it seems that it can prevent RV abnormalities. Therefore, the aim of this study was to investigate the possible protective effects of carvedilol in preventing RV dysfunction in patients with breast cancer treated with anthracyclines. The present single-blind clinical trial study was performed on 23 patients with breast cancer that 12 of them received only the anthracycline antineoplastic doxorubicin (Adriamycin The two parameters of RV ejection fraction and RV fractional area change in the carvedilol group with a mean of 66.41% ± 8.10% and 51.85% ± 6.89% were slightly higher than the control group with a mean of 64.58% ± 6.83% and 50.48 ± 5.79%, respectively, which was not statistically significant ( According to the results of the present study, the effect of using carvedilol as a preservative on improving RV function was seen compared to the control group, although this difference was not statistically significant.
Sections du résumé
Background
UNASSIGNED
Today, it has been shown that it is possible for right ventricular (RV) wall motion abnormalities or RV functional disorders to occur during cancer treatment. Now, considering the effect of carvedilol on beta 1, 2, and alpha receptors and its antioxidant properties, it seems that it can prevent RV abnormalities. Therefore, the aim of this study was to investigate the possible protective effects of carvedilol in preventing RV dysfunction in patients with breast cancer treated with anthracyclines.
Materials and Methods
UNASSIGNED
The present single-blind clinical trial study was performed on 23 patients with breast cancer that 12 of them received only the anthracycline antineoplastic doxorubicin (Adriamycin
Results
UNASSIGNED
The two parameters of RV ejection fraction and RV fractional area change in the carvedilol group with a mean of 66.41% ± 8.10% and 51.85% ± 6.89% were slightly higher than the control group with a mean of 64.58% ± 6.83% and 50.48 ± 5.79%, respectively, which was not statistically significant (
Conclusion
UNASSIGNED
According to the results of the present study, the effect of using carvedilol as a preservative on improving RV function was seen compared to the control group, although this difference was not statistically significant.
Identifiants
pubmed: 36926423
doi: 10.4103/abr.abr_134_21
pii: ABR-12-5
pmc: PMC10012032
doi:
Types de publication
Journal Article
Langues
eng
Pagination
5Informations de copyright
Copyright: © 2023 Advanced Biomedical Research.
Déclaration de conflit d'intérêts
There are no conflicts of interest.
Références
Eur Rev Med Pharmacol Sci. 2018 Apr;22(7):2175-2185
pubmed: 29687878
Int J Cardiol. 2013 Oct 15;168(6):5465-7
pubmed: 24090744
J Oncol. 2015;2015:609194
pubmed: 26339242
Eur J Echocardiogr. 2011 Nov;12(11):834-40
pubmed: 21880609
J Am Coll Cardiol. 2006 Dec 5;48(11):2258-62
pubmed: 17161256
J Am Soc Echocardiogr. 2019 Feb;32(2):277-285
pubmed: 30598366
Circ J. 2012;76(1):127-36
pubmed: 22033348
Circ J. 2011;75(9):2176-81
pubmed: 21778591
Eur J Heart Fail. 2018 May;20(5):907-909
pubmed: 29493056
Cardiol J. 2014;21(5):509-15
pubmed: 24142687
JAAPA. 2019 Oct;32(10):13-17
pubmed: 31513033
JACC Cardiovasc Imaging. 2018 Aug;11(8):1173-1186
pubmed: 30092972
Cancer Epidemiol. 2019 Feb;58:184-192
pubmed: 30639877
J Am Coll Cardiol. 2019 Jun 11;73(22):2859-2868
pubmed: 31171092